{
    "info": {
        "nct_id": "NCT03274076",
        "official_title": "Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study",
        "inclusion_criteria": "1. Diagnosis of systemic sclerosis (SSc), as classified using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc.\n2. Diffuse Cutaneous Systemic Sclerosis (dcSSc) as defined by 2001 LeRoy and Medsger\n3. Disease duration ≤ 60 months (defined as time from the first non-Raynaud phenomenon manifestation)\n4. Modified Rodnan Skin Score (mRSS) units ≥ 10 and ≤ 45 at screening.\n5. Agreement to receive varicella-zoster vaccination (Zostavax®) or have received vaccination prior to screening.\n6. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including the baseline visit.\n7. Ability to provide informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
        "exclusion_criteria": "1. Rheumatic disease other than dcSSc; it is acceptable to include patients with fibromyalgia, Sjogren syndrome, and scleroderma-associated myopathy\n2. Limited cutaneous SSc or sine scleroderma\n3. Major surgery (including joint surgery) within 8 weeks prior to baseline.\n4. Any infected ulcer at screening\n5. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, or bronchiectasis)\n6. Oral corticosteroids >10 mg/day of prednisone or equivalent.\n7. Hydroxychloroquine >400 mg/day, methotrexate >25 mg/week, D-Penicillamine >1000mg/day or mycophenolate mofetil > 2 grams/day prior to baseline. **Subjects can be on combination therapy of hydroxychloroquine and methotrexate or hydroxychloroquine and mycophenolate mofetil and must have been on a stable dose for at least 1 month prior to baseline visit.\n8. Prior history of treatment in the 3 months prior to baseline with biological disease modifying anti-rheumatic drugs (DMARDs)potent immunosuppressants such as cyclosporine and azathioprine\n9. Treatment with etanercept within ≤ 2 weeks of baseline: infliximab, certolizumab, golimumab, abatacept, tocilizumab, or adalimumab within ≤ 8 weeks of baseline; and anakinra within ≤ 1 week prior to the baseline visit.\n10. Intravenous corticosteroids within 2 weeks prior to baseline visit.\n11. Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 half-lives of the investigational drug, whichever is longer)\n12. Other investigational or marketed biologics with immunomodulatory properties within 3 months prior to baseline.\n13. Treatment with anti-CD20 6 months prior to baseline and B cell counts <LLN\n14. Any prior treatment with cell-depleting therapies other than anti-CD20 such as CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19\n15. Any prior treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation\n16. Vaccinated or exposed to a live/attenuated vaccine (other than Zostavax®) ≤ 6 weeks prior to baseline; or is expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study medication. (**See additional inclusion for obtaining Zostavax® prior to entering the study)\n17. Pulmonary disease with Forced Vital Capacity (FVC) ≤ 50% of predicted, or Diffusing capacity of the lungs for carbon monoxide (DLCO),(uncorrected for hemoglobin) ≤ 40% of predicted\n18. History of pulmonary arterial hypertension (PAH) with mean PAP> 30 mmHg on right heart catheterization requiring subcutaneous or intravenous prostacyclin or dual use of oral PAH therapies\n19. Subjects at risk for tuberculosis (TB):\n\n    A. Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; (TB results within 30 days of screening will be accepted and will not to be repeated. B. Latent TB at or within 30 days of screening, history of or current positive purified protein derivative tuberculin skin test (PPD) ( >5mm induration, regardless of Bacille Calmette Guerin [BCG] vaccine and/or QuantiFERON Gold, a negative chest x-ray, and no symptoms or risk factors), unless one month of prophylaxis has been completed prior to inclusion\n    * An indeterminate QuantiFERON® unless followed by a subsequent negative PPD or negative QuantiFERON® or a consultation with and clearance by local infectious disease (ID) department is required.\n20. Positive for hepatitis B surface antigen at or within 30 days of screening\n21. Positive for hepatitis C antigen at or within 30 days of screening\n22. Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.\n23. History of human immunodeficiency virus (HIV), (as determined by medical records or patient reported).\n24. History of diverticulitis or chronic, ulcerative lower gastrointestinal (GI) disease such as Crohns disease, ulcerative colitis, or other symptomatic, lower GI conditions that might predispose a patient to perforations.\n25. Pregnant or breastfeeding female subjects; and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug.\n26. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation and in the judgment of the investigator would make the subject inappropriate for entry into this study.\n27. History of systemic sclerosis (SSc) Renal Crisis within the 6 months prior to baseline.\n28. Any of the following lab results at screening:\n\n    * Hemoglobin <9 g/dL or Hematocrit <30%\n    * White Blood Cell count <3.0 x 109/L;\n    * Absolute Neutrophil count <1.2 x 109/L;\n    * White Blood Cell count <3.0 x 109/L;\n    * Absolute Neutrophil count <1.2 x 109/L;\n    * Platelet count <100 x 109/L;\n    * Absolute Lymphocyte count <0.75 x 109/L.\n    * ALT or AST > 1.5 × the upper limit of normal (ULN) of normal at screening or any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the patient's participation in the study\n    * Total bilirubin > upper limit of normal (ULN) at Screening.\n    * Estimated glomerular filtration rate [GFR] <40mL/min/1.73 m2\n29. Prior rituximab use without documentation of normalized b cell counts.\n30. History of recurrent (more than one episode) herpes zoster or disseminated (at least one episode) herpes zoster, or disseminated (at least one episode) herpes simplex\n31. History of any lymphoproliferative disorder, such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.\n32. History of any malignancy in the last 5 years with the exception of adequately treated or excised basal cell or squamous cell or cervical cancer in situ.\n33. Significant trauma or surgery procedure within 1 month prior to first dose of study drug.\n34. History of alcohol or substance abuse, unless in full remission for greater than 6 months prior to first dose of study drug.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "7. Ability to provide informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Ability to provide informed consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Disease duration ≤ 60 months (defined as time from the first non-Raynaud phenomenon manifestation)",
            "criterions": [
                {
                    "exact_snippets": "Disease duration ≤ 60 months",
                    "criterion": "disease duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Agreement to receive varicella-zoster vaccination (Zostavax®) or have received vaccination prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Agreement to receive varicella-zoster vaccination (Zostavax®) or have received vaccination prior to screening.",
                    "criterion": "varicella-zoster vaccination (Zostavax®)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to receive vaccination or prior receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 70 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 70 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Diffuse Cutaneous Systemic Sclerosis (dcSSc) as defined by 2001 LeRoy and Medsger",
            "criterions": [
                {
                    "exact_snippets": "Diffuse Cutaneous Systemic Sclerosis (dcSSc) as defined by 2001 LeRoy and Medsger",
                    "criterion": "Diffuse Cutaneous Systemic Sclerosis (dcSSc)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "as defined by 2001 LeRoy and Medsger"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Diagnosis of systemic sclerosis (SSc), as classified using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of systemic sclerosis (SSc)",
                    "criterion": "systemic sclerosis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as classified using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc",
                    "criterion": "systemic sclerosis classification (2013 ACR/EULAR)",
                    "requirements": [
                        {
                            "requirement_type": "classification_system",
                            "expected_value": "2013 American College of Rheumatology/European Union League Against Rheumatism"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including the baseline visit.",
            "criterions": [
                {
                    "exact_snippets": "Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) are permitted",
                    "criterion": "oral corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including the baseline visit",
                    "criterion": "oral corticosteroid dose regimen stability",
                    "requirements": [
                        {
                            "requirement_type": "duration of stable dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "prior to and including the baseline visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Modified Rodnan Skin Score (mRSS) units ≥ 10 and ≤ 45 at screening.",
            "criterions": [
                {
                    "exact_snippets": "Modified Rodnan Skin Score (mRSS) units ≥ 10 and ≤ 45 at screening.",
                    "criterion": "Modified Rodnan Skin Score (mRSS)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 45,
                                        "unit": "units"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "28. Any of the following lab results at screening:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following lab results at screening",
                    "criterion": "laboratory test results at screening",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Major surgery (including joint surgery) within 8 weeks prior to baseline.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (including joint surgery) within 8 weeks prior to baseline.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to baseline"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute Lymphocyte count <0.75 x 109/L.",
            "criterions": [
                {
                    "exact_snippets": "Absolute Lymphocyte count <0.75 x 109/L",
                    "criterion": "absolute lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0.75,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; (TB results within 30 days of screening will be accepted and will not to be repeated. B. Latent TB at or within 30 days of screening, history of or current positive purified protein derivative tuberculin skin test (PPD) ( >5mm induration, regardless of Bacille Calmette Guerin [BCG] vaccine and/or QuantiFERON Gold, a negative chest x-ray, and no symptoms or risk factors), unless one month of prophylaxis has been completed prior to inclusion",
            "criterions": [
                {
                    "exact_snippets": "history of active TB within the last 3 years, even if it was treated",
                    "criterion": "history of active TB",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type",
                    "criterion": "history of active TB",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment documentation",
                            "expected_value": "appropriate in duration and type"
                        }
                    ]
                },
                {
                    "exact_snippets": "current clinical, radiographic, or laboratory evidence of active TB",
                    "criterion": "active TB",
                    "requirements": [
                        {
                            "requirement_type": "evidence type",
                            "expected_value": [
                                "clinical",
                                "radiographic",
                                "laboratory"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Latent TB at or within 30 days of screening",
                    "criterion": "latent TB",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of or current positive purified protein derivative tuberculin skin test (PPD) ( >5mm induration, regardless of Bacille Calmette Guerin [BCG] vaccine and/or QuantiFERON Gold",
                    "criterion": "positive TB test",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "PPD (>5mm induration)",
                                "QuantiFERON Gold"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "a negative chest x-ray, and no symptoms or risk factors), unless one month of prophylaxis has been completed prior to inclusion",
                    "criterion": "latent TB with negative chest x-ray and no symptoms or risk factors",
                    "requirements": [
                        {
                            "requirement_type": "chest x-ray",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "risk factors",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "prophylaxis duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Vaccinated or exposed to a live/attenuated vaccine (other than Zostavax®) ≤ 6 weeks prior to baseline; or is expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study medication. (**See additional inclusion for obtaining Zostavax® prior to entering the study)",
            "criterions": [
                {
                    "exact_snippets": "Vaccinated or exposed to a live/attenuated vaccine (other than Zostavax®) ≤ 6 weeks prior to baseline",
                    "criterion": "live/attenuated vaccine (other than Zostavax®) vaccination or exposure",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination or exposure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "reference timepoint",
                            "expected_value": "prior to baseline"
                        }
                    ]
                },
                {
                    "exact_snippets": "is expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study medication",
                    "criterion": "live/attenuated vaccine (other than Zostavax®) vaccination or household exposure",
                    "requirements": [
                        {
                            "requirement_type": "expected occurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": [
                                "during treatment",
                                "during the 6 weeks following discontinuation of study medication"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White Blood Cell count <3.0 x 109/L;",
            "criterions": [
                {
                    "exact_snippets": "White Blood Cell count <3.0 x 109/L",
                    "criterion": "White Blood Cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Intravenous corticosteroids within 2 weeks prior to baseline visit.",
            "criterions": [
                {
                    "exact_snippets": "Intravenous corticosteroids within 2 weeks prior to baseline visit.",
                    "criterion": "intravenous corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to baseline visit"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. History of human immunodeficiency virus (HIV), (as determined by medical records or patient reported).",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute Neutrophil count <1.2 x 109/L;",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil count <1.2 x 109/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.2,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "33. Significant trauma or surgery procedure within 1 month prior to first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Significant trauma or surgery procedure within 1 month prior to first dose of study drug.",
                    "criterion": "significant trauma",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to first dose of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Significant trauma or surgery procedure within 1 month prior to first dose of study drug.",
                    "criterion": "surgery procedure",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Oral corticosteroids >10 mg/day of prednisone or equivalent.",
            "criterions": [
                {
                    "exact_snippets": "Oral corticosteroids >10 mg/day of prednisone or equivalent.",
                    "criterion": "oral corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day of prednisone or equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Pregnant or breastfeeding female subjects; and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... female subjects",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding female subjects",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception ... for the duration of the study and for at least 28 days after discontinuation of study drug",
                    "criterion": "contraception use in females of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "willingness/ability to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "contraception use duration",
                            "expected_value": "for the duration of the study and for at least 28 days after discontinuation of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation and in the judgment of the investigator would make the subject inappropriate for entry into this study.",
            "criterions": [
                {
                    "exact_snippets": "Severe acute or chronic medical or psychiatric condition",
                    "criterion": "medical or psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality that may increase risk associated with study participation",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "risk association with study participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the judgment of the investigator would make the subject inappropriate for entry into this study",
                    "criterion": "appropriateness for study entry (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "inappropriate for entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Pulmonary disease with Forced Vital Capacity (FVC) ≤ 50% of predicted, or Diffusing capacity of the lungs for carbon monoxide (DLCO),(uncorrected for hemoglobin) ≤ 40% of predicted",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary disease",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Forced Vital Capacity (FVC) ≤ 50% of predicted",
                    "criterion": "Forced Vital Capacity (FVC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "% of predicted"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Diffusing capacity of the lungs for carbon monoxide (DLCO),(uncorrected for hemoglobin) ≤ 40% of predicted",
                    "criterion": "Diffusing capacity of the lungs for carbon monoxide (DLCO) (uncorrected for hemoglobin)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 40,
                                "unit": "% of predicted"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White Blood Cell count <3.0 x 109/L;",
            "criterions": [
                {
                    "exact_snippets": "White Blood Cell count <3.0 x 109/L",
                    "criterion": "White Blood Cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Any prior treatment with cell-depleting therapies other than anti-CD20 such as CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment with cell-depleting therapies other than anti-CD20 such as CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19",
                    "criterion": "prior treatment with cell-depleting therapies (other than anti-CD20)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "32. History of any malignancy in the last 5 years with the exception of adequately treated or excised basal cell or squamous cell or cervical cancer in situ.",
            "criterions": [
                {
                    "exact_snippets": "History of any malignancy in the last 5 years",
                    "criterion": "malignancy history",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of adequately treated or excised basal cell or squamous cell or cervical cancer in situ",
                    "criterion": "basal cell or squamous cell or cervical cancer in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "adequately treated",
                                "excised"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute Neutrophil count <1.2 x 109/L;",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil count <1.2 x 109/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.2,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "27. History of systemic sclerosis (SSc) Renal Crisis within the 6 months prior to baseline.",
            "criterions": [
                {
                    "exact_snippets": "History of systemic sclerosis (SSc) Renal Crisis within the 6 months prior to baseline.",
                    "criterion": "systemic sclerosis (SSc) Renal Crisis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Limited cutaneous SSc or sine scleroderma",
            "criterions": [
                {
                    "exact_snippets": "Limited cutaneous SSc",
                    "criterion": "limited cutaneous systemic sclerosis (SSc)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sine scleroderma",
                    "criterion": "sine scleroderma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin <9 g/dL or Hematocrit <30%",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin <9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hematocrit <30%",
                    "criterion": "hematocrit",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "29. Prior rituximab use without documentation of normalized b cell counts.",
            "criterions": [
                {
                    "exact_snippets": "Prior rituximab use",
                    "criterion": "rituximab use",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without documentation of normalized b cell counts",
                    "criterion": "b cell counts",
                    "requirements": [
                        {
                            "requirement_type": "normalization documentation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, or bronchiectasis)",
            "criterions": [
                {
                    "exact_snippets": "any serious bacterial infection within the last 3 months",
                    "criterion": "serious bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless treated and resolved with antibiotics",
                    "criterion": "serious bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment and resolution with antibiotics",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any chronic bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, or bronchiectasis)",
                    "criterion": "chronic bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin > upper limit of normal (ULN) at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin > upper limit of normal (ULN) at Screening.",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "34. History of alcohol or substance abuse, unless in full remission for greater than 6 months prior to first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "History of alcohol or substance abuse",
                    "criterion": "alcohol or substance abuse history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless in full remission for greater than 6 months prior to first dose of study drug",
                    "criterion": "remission from alcohol or substance abuse",
                    "requirements": [
                        {
                            "requirement_type": "remission_status",
                            "expected_value": "full remission"
                        },
                        {
                            "requirement_type": "remission_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "31. History of any lymphoproliferative disorder, such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.",
            "criterions": [
                {
                    "exact_snippets": "History of any lymphoproliferative disorder",
                    "criterion": "lymphoproliferative disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Epstein Barr Virus (EBV) related lymphoproliferative disorder",
                    "criterion": "Epstein Barr Virus (EBV) related lymphoproliferative disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of lymphoma",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... leukemia",
                    "criterion": "leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "signs and symptoms suggestive of current lymphatic disease",
                    "criterion": "lymphatic disease",
                    "requirements": [
                        {
                            "requirement_type": "signs and symptoms suggestive of current disease",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALT or AST > 1.5 × the upper limit of normal (ULN) of normal at screening or any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the patient's participation in the study",
            "criterions": [
                {
                    "exact_snippets": "ALT or AST > 1.5 × the upper limit of normal (ULN) of normal at screening",
                    "criterion": "ALT or AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the patient's participation in the study",
                    "criterion": "clinically significant laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Prior history of treatment in the 3 months prior to baseline with biological disease modifying anti-rheumatic drugs (DMARDs)potent immunosuppressants such as cyclosporine and azathioprine",
            "criterions": [
                {
                    "exact_snippets": "Prior history of treatment in the 3 months prior to baseline with biological disease modifying anti-rheumatic drugs (DMARDs)",
                    "criterion": "treatment with biological DMARDs",
                    "requirements": [
                        {
                            "requirement_type": "history in past 3 months",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of treatment in the 3 months prior to baseline with ... potent immunosuppressants such as cyclosporine and azathioprine",
                    "criterion": "treatment with potent immunosuppressants (e.g., cyclosporine, azathioprine)",
                    "requirements": [
                        {
                            "requirement_type": "history in past 3 months",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated glomerular filtration rate [GFR] <40mL/min/1.73 m2",
            "criterions": [
                {
                    "exact_snippets": "Estimated glomerular filtration rate [GFR] <40mL/min/1.73 m2",
                    "criterion": "estimated glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 40,
                                "unit": "mL/min/1.73 m2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An indeterminate QuantiFERON® unless followed by a subsequent negative PPD or negative QuantiFERON® or a consultation with and clearance by local infectious disease (ID) department is required.",
            "criterions": [
                {
                    "exact_snippets": "An indeterminate QuantiFERON® unless followed by a subsequent negative PPD or negative QuantiFERON® or a consultation with and clearance by local infectious disease (ID) department is required.",
                    "criterion": "QuantiFERON test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "not indeterminate, or if indeterminate, must be followed by a subsequent negative PPD or negative QuantiFERON, or clearance by infectious disease department"
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Positive for hepatitis B surface antigen at or within 30 days of screening",
            "criterions": [
                {
                    "exact_snippets": "Positive for hepatitis B surface antigen at or within 30 days of screening",
                    "criterion": "hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days from screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Subjects at risk for tuberculosis (TB):",
            "criterions": [
                {
                    "exact_snippets": "Subjects at risk for tuberculosis (TB)",
                    "criterion": "risk for tuberculosis (TB)",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count <100 x 109/L;",
            "criterions": [
                {
                    "exact_snippets": "Platelet count <100 x 109/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Any infected ulcer at screening",
            "criterions": [
                {
                    "exact_snippets": "Any infected ulcer at screening",
                    "criterion": "ulcer infection status",
                    "requirements": [
                        {
                            "requirement_type": "infection presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Rheumatic disease other than dcSSc; it is acceptable to include patients with fibromyalgia, Sjogren syndrome, and scleroderma-associated myopathy",
            "criterions": [
                {
                    "exact_snippets": "Rheumatic disease other than dcSSc",
                    "criterion": "rheumatic disease",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "any rheumatic disease except dcSSc, fibromyalgia, Sjogren syndrome, and scleroderma-associated myopathy"
                        }
                    ]
                },
                {
                    "exact_snippets": "it is acceptable to include patients with fibromyalgia, Sjogren syndrome, and scleroderma-associated myopathy",
                    "criterion": "fibromyalgia, Sjogren syndrome, scleroderma-associated myopathy",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "fibromyalgia",
                                "Sjogren syndrome",
                                "scleroderma-associated myopathy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "30. History of recurrent (more than one episode) herpes zoster or disseminated (at least one episode) herpes zoster, or disseminated (at least one episode) herpes simplex",
            "criterions": [
                {
                    "exact_snippets": "History of recurrent (more than one episode) herpes zoster",
                    "criterion": "herpes zoster",
                    "requirements": [
                        {
                            "requirement_type": "history of recurrence",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "episode"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "disseminated (at least one episode) herpes zoster",
                    "criterion": "disseminated herpes zoster",
                    "requirements": [
                        {
                            "requirement_type": "history of dissemination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "episode"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "disseminated (at least one episode) herpes simplex",
                    "criterion": "disseminated herpes simplex",
                    "requirements": [
                        {
                            "requirement_type": "history of dissemination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "episode"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. History of pulmonary arterial hypertension (PAH) with mean PAP> 30 mmHg on right heart catheterization requiring subcutaneous or intravenous prostacyclin or dual use of oral PAH therapies",
            "criterions": [
                {
                    "exact_snippets": "History of pulmonary arterial hypertension (PAH)",
                    "criterion": "pulmonary arterial hypertension (PAH)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "mean PAP> 30 mmHg on right heart catheterization",
                    "criterion": "mean pulmonary arterial pressure (PAP) on right heart catheterization",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring subcutaneous or intravenous prostacyclin or dual use of oral PAH therapies",
                    "criterion": "PAH therapy requirement",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "subcutaneous prostacyclin",
                                "intravenous prostacyclin",
                                "dual use of oral PAH therapies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Hydroxychloroquine >400 mg/day, methotrexate >25 mg/week, D-Penicillamine >1000mg/day or mycophenolate mofetil > 2 grams/day prior to baseline. **Subjects can be on combination therapy of hydroxychloroquine and methotrexate or hydroxychloroquine and mycophenolate mofetil and must have been on a stable dose for at least 1 month prior to baseline visit.",
            "criterions": [
                {
                    "exact_snippets": "Hydroxychloroquine >400 mg/day",
                    "criterion": "hydroxychloroquine dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 400,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "methotrexate >25 mg/week",
                    "criterion": "methotrexate dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "mg/week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "D-Penicillamine >1000mg/day",
                    "criterion": "D-Penicillamine dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1000,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "mycophenolate mofetil > 2 grams/day",
                    "criterion": "mycophenolate mofetil dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "grams/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "combination therapy of hydroxychloroquine and methotrexate or hydroxychloroquine and mycophenolate mofetil ... must have been on a stable dose for at least 1 month prior to baseline visit",
                    "criterion": "combination therapy and dose stability",
                    "requirements": [
                        {
                            "requirement_type": "combination therapy",
                            "expected_value": [
                                "hydroxychloroquine and methotrexate",
                                "hydroxychloroquine and mycophenolate mofetil"
                            ]
                        },
                        {
                            "requirement_type": "dose stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Positive for hepatitis C antigen at or within 30 days of screening",
            "criterions": [
                {
                    "exact_snippets": "Positive for hepatitis C antigen at or within 30 days of screening",
                    "criterion": "hepatitis C antigen",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at or within 30 days of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 half-lives of the investigational drug, whichever is longer)",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 half-lives of the investigational drug, whichever is longer)",
                    "criterion": "treatment with investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. History of diverticulitis or chronic, ulcerative lower gastrointestinal (GI) disease such as Crohns disease, ulcerative colitis, or other symptomatic, lower GI conditions that might predispose a patient to perforations.",
            "criterions": [
                {
                    "exact_snippets": "History of diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic, ulcerative lower gastrointestinal (GI) disease such as Crohns disease, ulcerative colitis",
                    "criterion": "chronic, ulcerative lower gastrointestinal (GI) disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Crohns disease",
                    "criterion": "Crohn's disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other symptomatic, lower GI conditions that might predispose a patient to perforations",
                    "criterion": "symptomatic lower GI conditions predisposing to perforations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Treatment with etanercept within ≤ 2 weeks of baseline: infliximab, certolizumab, golimumab, abatacept, tocilizumab, or adalimumab within ≤ 8 weeks of baseline; and anakinra within ≤ 1 week prior to the baseline visit.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with etanercept within ≤ 2 weeks of baseline",
                    "criterion": "etanercept treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "infliximab, certolizumab, golimumab, abatacept, tocilizumab, or adalimumab within ≤ 8 weeks of baseline",
                    "criterion": "infliximab, certolizumab, golimumab, abatacept, tocilizumab, or adalimumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anakinra within ≤ 1 week prior to the baseline visit",
                    "criterion": "anakinra treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Treatment with anti-CD20 6 months prior to baseline and B cell counts <LLN",
            "criterions": [
                {
                    "exact_snippets": "Treatment with anti-CD20 6 months prior to baseline",
                    "criterion": "anti-CD20 treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to baseline"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "B cell counts <LLN",
                    "criterion": "B cell counts",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "LLN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Other investigational or marketed biologics with immunomodulatory properties within 3 months prior to baseline.",
            "criterions": [
                {
                    "exact_snippets": "Other investigational or marketed biologics with immunomodulatory properties within 3 months prior to baseline.",
                    "criterion": "use of investigational or marketed biologics with immunomodulatory properties",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to baseline"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Any prior treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation",
            "criterions": [
                {
                    "exact_snippets": "Any prior treatment with chlorambucil",
                    "criterion": "prior treatment with chlorambucil",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior treatment with ... bone marrow transplantation",
                    "criterion": "prior treatment with bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior treatment with ... total lymphoid irradiation",
                    "criterion": "prior treatment with total lymphoid irradiation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "22. Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.",
            "criterions": [
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant renal ... disease",
                    "criterion": "renal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant hepatic ... disease",
                    "criterion": "hepatic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant hematologic ... disease",
                    "criterion": "hematologic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant gastrointestinal ... disease",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant metabolic ... disease",
                    "criterion": "metabolic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant endocrine ... disease",
                    "criterion": "endocrine disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant pulmonary ... disease",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant cardiac ... disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent history of uncontrolled clinically significant neurologic ... disease",
                    "criterion": "neurologic disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "current",
                                "recent"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}